赛伦生物
(688163)
| 流通市值：30.76亿 | | | 总市值：30.76亿 |
| 流通股本：1.08亿 | | | 总股本：1.08亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 27,093,556.95 | 196,205,881.77 | 175,138,574.09 | 100,819,362.78 |
| 营业总成本 | 28,203,094.58 | 140,513,815.84 | 105,193,973.75 | 64,302,763.21 |
| 其他经营收益 | | | | |
| 营业利润 | 473,020.43 | 64,507,072.1 | 75,030,437.29 | 37,897,895.42 |
| 利润总额 | 420,443.75 | 64,206,211.65 | 74,817,469.4 | 37,765,257.67 |
| 净利润 | 567,176.15 | 51,787,396.52 | 64,210,654.81 | 32,976,733.37 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 567,176.15 | 51,787,396.52 | 64,210,654.81 | 32,976,733.37 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 891,372,550.64 | 912,161,711.53 | 917,509,990.82 | 907,902,466.37 |
| 非流动资产: | | | | |
| 非流动资产合计 | 262,999,660.3 | 245,048,695.71 | 244,024,044.52 | 227,625,506.47 |
| 资产总计 | 1,154,372,210.94 | 1,157,210,407.24 | 1,161,534,035.34 | 1,135,527,972.84 |
| 流动负债: | | | | |
| 流动负债合计 | 33,770,323.9 | 36,907,134.6 | 31,950,988.77 | 23,983,968.02 |
| 非流动负债: | | | | |
| 非流动负债合计 | 7,377,105.62 | 7,645,667.37 | 4,502,183.01 | 4,710,662.7 |
| 负债合计 | 41,147,429.52 | 44,552,801.97 | 36,453,171.78 | 28,694,630.72 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,113,224,781.42 | 1,112,657,605.27 | 1,125,080,863.56 | 1,106,833,342.12 |
| 股东权益合计 | 1,113,224,781.42 | 1,112,657,605.27 | 1,125,080,863.56 | 1,106,833,342.12 |
| 负债和股东权益合计 | 1,154,372,210.94 | 1,157,210,407.24 | 1,161,534,035.34 | 1,135,527,972.84 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 21,032,697.11 | 197,802,661.06 | 144,840,352.73 | 41,955,370.67 |
| 经营活动现金流出小计 | 32,800,993.32 | 137,269,758.87 | 106,674,065.51 | 63,190,394.71 |
| 经营活动产生的现金流量净额 | -11,768,296.21 | 60,532,902.19 | 38,166,287.22 | -21,235,024.04 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 767,089,922.73 | 2,315,420,107.56 | 1,643,240,887.64 | 902,841,916.86 |
| 投资活动现金流出小计 | 735,839,872.94 | 2,489,505,148.06 | 1,753,667,963.21 | 908,857,027.61 |
| 投资活动产生的现金流量净额 | 31,250,049.79 | -174,085,040.5 | -110,427,075.57 | -6,015,110.75 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 117,000 | 35,319,877.5 | 35,085,877.5 | 21,642,000 |
| 筹资活动产生的现金流量净额 | -117,000 | -35,319,877.5 | -35,085,877.5 | -21,642,000 |
| 汇率变动对现金及现金等价物的影响 | -7,453.25 | 45,884.27 | 187,559.98 | 126,231.44 |
| 现金及现金等价物净增加额 | 19,357,300.33 | -148,826,131.54 | -107,159,105.87 | -48,765,903.35 |
| 期末现金及现金等价物余额 | 52,638,306.01 | 33,281,005.68 | 74,948,031.35 | 133,341,233.87 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -148,826,131.54 | - | -48,765,903.35 |